Syndax Pharmaceuticals, Inc. (SNDX)
Nasdaq · Healthcare · Biotechnology
$17.83+1.31%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.6B
- 52-week range
- $12.99 – $25.59
- 52-week change
- +6.99%
- EPS (trailing)
- −$2.52
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $172M (+627.83%)
- Net income
- −$285M
- Operating margin
- −158.4%
- Diluted EPS
- −$3.29
- Free cash flow
- −$323M
From the company’s annual report on SEC EDGAR.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Headquarters: New York, United States · 298 employees · syndax.com